Prostaglandin E2-Glyceryl Ester: In Vivo Evidence for a Distinct Pharmacological Identity from Intraocular Pressure Studies
- 1 August 2016
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 358 (2) , 173-180
Abstract
Prostaglandin E2 (PGE2)-2-glyceryl ester is a COX-2 product of the endocannabinoid 2-arachidonyl glycerol. It is claimed as pharmacologically novel but this is complicated by rapid and irreversible isomerization to the 1(3) ester. For ocular studies, enzymatic hydrolysis of the ester moiety creates an additional complication. PG-glyceryl esters were stabilized to isomerization and hydrolysis by replacing the non-carbonyl O with NH, to form the serinolamide and propanediolamide as stable analogs of PG-2-glyceryl and -1(3) glyceryl esters, respectively. Intraocular pressure was measured in conscious dogs and conscious laser induced ocular hypertensive monkeys. Pharmacological studies involved stable transfectants for each of the human recombinant prostanoid receptors and the isolated feline iris for prostamide activity. PGE2-serinolamide and PGE2- propanediolamide were essentially inactive at all receptors except the EP3 receptor (E.C.50 ~500nM). This obliged elucidation of EP3 receptor involvement in the intraocular pressure response to these PGE2-glycyerl ester analogs. Since the EP3 receptor agonists, sulprostone and GR 63799, did not lower monkey intraocular pressure, a role for EP3 receptors in mediating the effects of PGE2-serinolamide and PGE2-propanediolamide is not indicated. PGE2-glyceryl ester (0.01% and 0.1%) substantially lowered intraocular pressure in monkeys. PGE2- propanediolamide was more efficacious than PGE2-serinolamide in lowering intraocular pressure in monkey eyes but both appeared equi-effective in dog eyes. PGE2-serinolamide dose-dependently (0.01- 0.1%) lowered intraocular pressure in both species but PGF2α-serinolamide was inactive. In conclusion, stable PGE2-glyceryl ester analogs lowered intraocular pressure. These findings are consistent with the presence of a PGE2-glyceryl ester specific recognition site in the eye.Keywords
This publication has 27 references indexed in Scilit:
- Cyclooxygenase-2, prostaglandin E2 glycerol ester and nitric oxide are involved in muscarine-induced presynaptic enhancement at the vertebrate neuromuscular junctionThe Journal of Physiology, 2013
- Structural determinants for calcium mobilization by prostaglandin E2 and prostaglandin F2α glyceryl esters in RAW 264.7 cells and H1819 cellsProstaglandins & Other Lipid Mediators, 2010
- Prostaglandin Subtype-Selective and Non-Selective IOP-Lowering Comparison in MonkeysJournal of Ocular Pharmacology and Therapeutics, 2009
- Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexesBritish Journal of Pharmacology, 2008
- Prostaglandin E2 glycerol ester, an endogenous COX‐2 metabolite of 2‐arachidonoylglycerol, induces hyperalgesia and modulates NFκB activityBritish Journal of Pharmacology, 2008
- The Prostanoid EP2Receptor Agonist Butaprost Increases Uveoscleral Outflow in the Cynomolgus MonkeyInvestigative Ophthalmology & Visual Science, 2006
- Prostaglandin Ethanolamides (Prostamides): In Vitro Pharmacology and MetabolismThe Journal of Pharmacology and Experimental Therapeutics, 2004
- The glyceryl ester of prostaglandin E2mobilizes calcium and activates signal transduction in RAW264.7 cellsProceedings of the National Academy of Sciences, 2004
- Metabolism of the Endocannabinoids, 2-Arachidonylglycerol and Anandamide, into Prostaglandin, Thromboxane, and Prostacyclin Glycerol Esters and EthanolamidesJournal of Biological Chemistry, 2002
- Metabolism of Prostaglandin Glycerol Esters and Prostaglandin Ethanolamides in Vitro and in VivoJournal of Biological Chemistry, 2001